Thursday, December 02, 2021

NEWS

MedRxiv website discloses results on Cuba’s Abdala vaccine

MedRxiv website discloses results on Cuba’s Abdala vaccine

Havana, Oct 20 (Prensa Latina) The medRxiv website, dedicated to distributing unpublished texts on medicine, on Wednesday released research results concerning Cuba´s Abdala vaccine candidate.
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

Using Elecsys® anti-SARS-CoV-2 test, we assessed 42 people vaccinated with Abdala candidate and 15 days after immunization their sera showed high antibody titers, the Cuban scientists stated.

There was a high correlation between the Cuban UMELISA SARS-CoV-2 antiRBD test used during clinical trials and the conclusions of Roche’s Elecsys®.

Those who received Abdala vaccine candidate achieved antibody titers through Elecsys® anti-SARS-CoV-2 comparable to those of Pfizer / BionTech vaccines when using the same test.

Abdala candidate, authorized by national regulatory authorities for emergency use, proved high effectiveness (92.28%) in phase III of clinical trials to reduce transmission, and over 90% to cut down severity and mortality rates.

Soberana 02 and Soberana Plus vaccine candidates, both developed by the Finlay Vaccine Institute (FVI), showed 91.2% effectiveness during their clinical trials.

pgh/pll / mgt / znc

RELATED
ÚLTIMO MINUTO
name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.